Trade-Ideas: DexCom (DXCM) Is Today's New Lifetime High Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified DexCom ( DXCM) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified DexCom as such a stock due to the following factors:

  • DXCM has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $138.1 million
  • DXCM has traded 124,438 shares today
  • DXCM is trading at a new lifetime high

EXCLUSIVE OFFER: Get the inside scoop on opportunities in DXCM with the Ticky from Trade-Ideas. See the FREE profile for DXCM NOW at Trade-Ideas

More details on DXCM:

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are nine analysts that rate DexCom a buy, one analyst rates it a sell, and three rate it a hold.

The average volume for DexCom has been 667,400 shares per day over the past 30 days. DexCom has a market cap of $6.17 billion and is part of the health care sector and health services industry. The stock has a beta of 0.79 and a short float of 4.5% with 2.18 days to cover. Shares are up 44.6% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Apple Watch Is on Its Way to Becoming a $6 Billion Business, but Is That Really Enough?

DexCom Shares Rise After FDA Approves G5 Mobile App for Android Devices

Apple Watch Appears on Its Way to Becoming a $6 Billion Business

DexCom Stock Surging on Apple Watch Partnership

Markets Down? Get Used to It: Cramer's 'Mad Money' Recap (Wednesday 5/17/17)